SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS) ("Erasca"), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 21,844,660 shares of its common stock in an oversubscribed private placement at a price of $2.06 per share. Erasca a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40602 ERASCA, INC. (Exact name of Registrant as specified in its Charter) | Delaware | | 83-1217027 | | --- | --- | --- | | (State or ...

Exhibit 99.1 Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS- 007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of Dec ...

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initial SEACRAFT-1 Phase 1b combination data in RAS Q61X solid tumors expected between Q2-Q4 2024 Initiation of pivotal SEACRAFT-2 in NRASm melanoma expected in H1 2024 SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ______________ Commission File Number: 001-40602 ERASCA, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ______________ Commission File Number: 001-40602 ERASCA, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdictio ...

Product Development - The company plans to initiate a pivotal Phase 3 trial for its lead product candidate, naporafenib, in NRAS-mutated melanoma patients in the first half of 2024, following a Phase 1b trial in the second half of 2023[94]. - Naporafenib has been dosed in over 500 patients, establishing safety, tolerability, pharmacokinetics, and pharmacodynamics, with clinical proof-of-concept data in combination with trametinib for NRAS-mutated melanoma[94]. - The development strategy for naporafenib could potentially address approximately 3.5 million patients worldwide, significantly expanding the total addressable patient population[95]. - The company has executed a clinical trial collaboration with Novartis for the SEACRAFT-1 trial, where Novartis will provide trametinib at no cost[95]. - ERAS-007 and ERAS-601 are the next most advanced product candidates, targeting downstream and upstream nodes of the RAS/MAPK pathway, respectively[96]. - The HERKULES clinical trials for ERAS-007 are exploring both monotherapy and combinations across multiple tumor types, including NSCLC and CRC[96]. - The FDA granted Fast Track Designation to ERAS-801 for treating adult patients with glioblastoma multiforme with EGFR gene alterations, facilitating early interactions during clinical development[100]. Financial Performance - The net loss for the three months ended March 31, 2023, was $33.2 million, a decrease from a net loss of $36.5 million for the same period in 2022, reflecting a reduction of $3.3 million[106][120]. - Research and development expenses for the three months ended March 31, 2023, were $27.6 million, slightly up from $27.4 million in the same period of 2022, with a notable increase in facilities-related expenses[121]. - General and administrative expenses increased to $9.4 million for the three months ended March 31, 2023, compared to $7.1 million in the same period of 2022, marking an increase of $2.4 million[123]. - Total operating expenses for the three months ended March 31, 2023, were $37.0 million, a slight increase from $36.5 million in the same period of 2022[120]. - Interest income for the three months ended March 31, 2023, was $3.8 million, significantly up from $47,000 in the same period of 2022, primarily due to increased interest earned on cash and marketable securities[124]. - The company reported a net cash used in operating activities of $26.4 million for the three months ended March 31, 2023, compared to $25.8 million for the same period in 2022[132][133]. - Net cash provided by investing activities was $14.7 million for the three months ended March 31, 2023, a significant increase from cash used in investing activities of $1.8 million in the same period of 2022[134]. - Cash generated from financing activities was $0.2 million for the three months ended March 31, 2023, compared to $0.5 million in the same period of 2022[135]. Capital Resources - The company completed a stock offering in December 2022, issuing 15,384,616 shares at $6.50 per share, resulting in net proceeds of $94.9 million[102]. - As of March 31, 2023, the company has raised a total of $765.4 million to fund operations, with cash, cash equivalents, and marketable securities amounting to $389.7 million[105]. - The company expects its cash resources will be sufficient to fund operations into the second half of 2025[107]. - As of March 31, 2023, the company had cash, cash equivalents, and marketable securities totaling $389.7 million, expected to fund operations into the second half of 2025[128]. - The company has no committed sources of capital and plans to finance future cash needs primarily through equity offerings, debt financing, or collaborations[130]. - The company anticipates that future capital requirements will depend on various factors, including the costs and timing of clinical trials and regulatory reviews[129]. - The company faces risks and uncertainties regarding its financial resources, which could deplete sooner than expected due to various operational costs and market conditions[128]. Operational Strategy - The company relies on third parties for manufacturing and distribution of its product candidates, aiming to maintain an efficient infrastructure[101]. - The company has assembled a pipeline of 12 disclosed programs focused on the RAS/MAPK pathway, positioning itself as a leader in precision oncology[90]. - The company has entered into in-license and acquisition agreements for certain intellectual property rights related to product candidates and development programs[110]. - The company incurred no in-process research and development expenses for the three months ended March 31, 2023, compared to $2.0 million for the same period in 2022, which was related to a milestone payment[122].

234 55 55 35 225 120 260 126 10 ERAS-3490 56 1,221 1,687 483 Erasca's naporafenib pan-RAFi could address unmet needs P P P Autophagy MAPK pathway ULK PI3K pathway RAS-GTP GRB2 SHP2 GAP GDP GTP P1 NF1 SOS1 RAF MEK PI3K AKT mTOR RAS-GDP EGFR/ Other FLT3 RTKs MYC GEF ERK naporafenib BRAF CRAF RAS Q61X Solid Tumors 157,000 NRASm Melanoma 54,000 NF1 Loss-of-Function 234,000 BRAF Class II/III Solid 55,000 11 | --- | --- | |--------------------------------------|------------| | Assay | Value (nM) | | Biochemical C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40602 ERASCA, INC. (Exact name of Registrant as specified in its Charter) Delaware 83-1217027 (State or other jurisdiction of incorpo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☑ Smaller reporting company ☑ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ______________ Commission File Number: 00 ...